Ecopipam (Psyadon Pharmaceuticals) success in Phase II study for Tourette Syndrome

Psyadon Pharmaceuticals, Inc. announced that its Phase II study of ecopipam in patients with Tourette Syndrome was stopped early when a planned interim analysis revealed a statistically significant reduction in the severity of the patients' tic symptoms. This decision was supported by both the independent Drug Safety and Monitoring Committee overseeing the study and by the external Research Committee established as part of Psyadon's partnership with the Tourette Syndrome Association - the nation's largest patient advocacy group for this disorder.There has not been any new treatments for Tourette Syndrome approved by the FDA in over twenty years.